OXFORD, United Kingdom, Aug. 24, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its second quarter financial results for the period ending 31 July 2015 on Thursday, 27 August 2015.
Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the second quarter results press release and a replay of the call will also be available through the Company's website, www.summitplc.com.
- END -
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
| For more information, please contact: | |
| Summit Therapeutics | |
| Glyn Edwards / Richard Pye (UK office) | Tel: +44 (0)1235 443 951 |
| Erik Ostrowski (US office) | +1 617 294 6607 |
| Cairn Financial Advisers LLP | |
| (Nominated Adviser) | |
| Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7148 7900 |
| N+1 Singer | |
| (Broker) | |
| Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 |
| MacDougall Biomedical Communications | |
| (US media contact) | Tel: +1 781 235 3060 |
| Michelle Avery | mavery@macbiocom.com |
| Peckwater PR | |
| (Financial public relations, UK) | Tel: +44 (0)7879 458 364 |
| Tarquin Edwards | tarquin.edwards@peckwaterpr.co.uk |